200 related articles for article (PubMed ID: 23590314)
1. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
3. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
5. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
Maat W; Beiboer SH; Jager MJ; Luyten GP; Gruis NA; van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1291-8. PubMed ID: 18385040
[TBL] [Abstract][Full Text] [Related]
8. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Furuta J; Nobeyama Y; Umebayashi Y; Otsuka F; Kikuchi K; Ushijima T
Cancer Res; 2006 Jun; 66(12):6080-6. PubMed ID: 16778180
[TBL] [Abstract][Full Text] [Related]
9. Methylation subtypes and large-scale epigenetic alterations in gastric cancer.
Zouridis H; Deng N; Ivanova T; Zhu Y; Wong B; Huang D; Wu YH; Wu Y; Tan IB; Liem N; Gopalakrishnan V; Luo Q; Wu J; Lee M; Yong WP; Goh LK; Teh BT; Rozen S; Tan P
Sci Transl Med; 2012 Oct; 4(156):156ra140. PubMed ID: 23076357
[TBL] [Abstract][Full Text] [Related]
10. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.
Hallberg AR; Vorrink SU; Hudachek DR; Cramer-Morales K; Milhem MM; Cornell RA; Domann FE
Epigenetics; 2014 Dec; 9(12):1641-7. PubMed ID: 25625848
[TBL] [Abstract][Full Text] [Related]
11. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.
Nagasawa T; Zhang Q; Raghunath PN; Wong HY; El-Salem M; Szallasi A; Marzec M; Gimotty P; Rook AH; Vonderheid EC; Odum N; Wasik MA
Leuk Res; 2006 Mar; 30(3):303-12. PubMed ID: 16185764
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA regulation of melanoma progression.
Bonazzi VF; Stark MS; Hayward NK
Melanoma Res; 2012 Apr; 22(2):101-13. PubMed ID: 22209751
[TBL] [Abstract][Full Text] [Related]
13. DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis.
Foltz G; Yoon JG; Lee H; Ryken TC; Sibenaller Z; Ehrich M; Hood L; Madan A
Oncogene; 2009 Jul; 28(29):2667-77. PubMed ID: 19465937
[TBL] [Abstract][Full Text] [Related]
14. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
15. Aberrant p27Kip1 promoter methylation in malignant melanoma.
Worm J; Bartkova J; Kirkin AF; Straten P; Zeuthen J; Bartek J; Guldberg P
Oncogene; 2000 Oct; 19(44):5111-5. PubMed ID: 11042700
[TBL] [Abstract][Full Text] [Related]
16. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
18. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.
Hong C; Moorefield KS; Jun P; Aldape KD; Kharbanda S; Phillips HS; Costello JF
Proc Natl Acad Sci U S A; 2007 Jun; 104(26):10974-9. PubMed ID: 17578925
[TBL] [Abstract][Full Text] [Related]
19. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
Tanaka K; Imoto I; Inoue J; Kozaki K; Tsuda H; Shimada Y; Aiko S; Yoshizumi Y; Iwai T; Kawano T; Inazawa J
Oncogene; 2007 Sep; 26(44):6456-68. PubMed ID: 17438526
[TBL] [Abstract][Full Text] [Related]
20. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
